Aside from the inclusion of a few new CIDP patients in comparison to previous studies15,18, the novelty of our work relies on describing one new CNTN1 positive patient, one new NF155 positive patient, one patient positive for PMP2 and 11 CIDP patients with anti-ganglioside antibodies. This evidence concerns the gene CNTN1 and chronic inflammatory demyelinating polyradiculoneuropathy.